September 2026
M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30

Maxime Dely: Guillain-Barré Syndrome – What if the Key Lies in the Plasma?

Maxime Dely/ LinkedIn

Sep 8, 2026, 15:48

Maxime Dely: Guillain-Barré Syndrome – What if the Key Lies in the Plasma?

Maxime Dely, Therapeutic Solutions Sales Consultant at Terumo Blood and Cell Technologies, shared a post on LinkedIn:

“Guillain-Barré syndrome: what if the key lies in the plasma?

Guillain-Barré syndrome is an acute inflammatory neuropathy in which autoimmune mechanisms target the peripheral nervous system. Depending on the subtype, autoantibodies, immune complexes, and inflammatory mediators contribute to axonal or demyelinating injury.

This is where therapeutic plasma exchange becomes particularly relevant.

Through blood component separation, notably by centrifugation, apheresis enables the removal of a significant fraction of the patient’s plasma, which is then replaced with an appropriate substitution fluid.

The objective: achieve high plasma clearance within a limited number of sessions, rapidly reducing the concentration of circulating pathogenic factors.

This is the strength of apheresis: directly targeting the biological compartment that carries key mediators of the pathological immune response.

A separation technology that becomes a genuine therapeutic tool.

And behind every extracorporeal circuit, there is ultimately one goal: buying time when every hour matters.”

Maxime Dely